American Home Products
This article was originally published in The Gray Sheet
Executive Summary
Use of rhBMP-2 bone morphogenic protein product for long-bone fractures is expected by the firm's Genetics Institute unit to go before FDA's Orthopedics and Rehabilitation Devices Advisory Panel by the end of 2002. The firm received a not-approvable letter for the indication June 22 due to problems with the initial clinical trial design and data interpretation (1"The Gray Sheet" June 25, 2001, p. 27). Stryker's OP-1 will be the first bone morphogenic protein product on the market following humanitarian device exemption clearance for long-bone non-union fractures, announced Oct. 17 (2"The Gray Sheet" Oct. 22, 2001, p. 20). AHP hopes to be on the market in early 2003
You may also be interested in...
Stryker OP-1 Gains HDE Status For Failed Long-Bone Nonunion Fractures
Stryker plans to begin making its OP-1 (Osteogenic Protein 1) bone morphogenetic protein implant available in the U.S. by year-end under a humanitarian device exemption received from FDA Oct. 17, becoming the first company to have a BMP product reach the U.S. market.
WGT Gains EMI Filtering Technology For OEM Sales Through Maxwell’s Sierra
Wilson Greatbatch Technologies is adding electromagnetic interference (EMI) filtering technology to its implantable device component supply business through the acquisition of Maxwell Technologies' Sierra medical electronics unit
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.